U-Bisys Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

U-Bisys General Information

Description

Developer of human antibodies and antibody-derivatives for therapeutic and diagnostic purposes. The company's human antibodies and antibody-derivatives technology, MAbstract, is subtractive phage antibody-display selection technology offed by the company.

Contact Information

Website
www.u-bisys.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Heidelberglaan
  • 3584 Utrecht
  • Netherlands
Primary Industry
Biotechnology
Acquirer
Crucell
Corporate Office
  • Heidelberglaan
  • 3584 Utrecht
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

U-Bisys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 30-Jun-2000 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view U-Bisys’s complete valuation and funding history, request access »

U-Bisys Patents

  • 17

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

U-Bisys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1188771-A1 Libraries of human heavy chain variable fragments in a functional format Inactive 15-Sep-2000
EP-1184458-A1 Differentially expressed cd46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof Inactive 28-Aug-2000
EP-1174440-A1 A selectively-expressed epitope on the human cd38 molecule detected by a phage display library-derived human scfv antibody fragment Inactive 19-Jul-2000
EP-1001017-A1 Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules Inactive 16-Oct-1998
WO-2000023570-A1 Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules Inactive 16-Oct-1998 C12N5/0006
To view U-Bisys’s complete patent history, request access »

U-Bisys Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
EQT Life Sciences Venture Capital Minority
To view U-Bisys’s complete investors history, request access »

Ready to get started?

Request a free trial

U-Bisys FAQs

  • When was U-Bisys founded?

    U-Bisys was founded in 1996.

  • Where is U-Bisys headquartered?

    U-Bisys is headquartered in Utrecht, Netherlands.

  • What industry is U-Bisys in?

    U-Bisys’s primary industry is Biotechnology.

  • Is U-Bisys a private or public company?

    U-Bisys is a Private company.

  • What is U-Bisys’s current revenue?

    The current revenue for U-Bisys is .

  • Who are U-Bisys’s investors?

    EQT Life Sciences has invested in U-Bisys.

  • When was U-Bisys acquired?

    U-Bisys was acquired on 30-Jun-2000.

  • Who acquired U-Bisys?

    U-Bisys was acquired by Crucell.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process